FGF23 and chronic kidney disease: For regular monitoring of hearing status, FGF23 and D-serine levels are needed to assess the risk of hearing impairment in patients with chronic renal failure in order to prevent and detect hearing impairment in a timely manner and to reduce the increased disability, decreased quality of life, and increased disease burden in patients with chronic renal failure due to hearing loss.